Concord Drugs Ltd

Fri 4/09/2026,15:25:0 | BSE : CONCORD

₹80.800.49 (0.61%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 81.80

Previous Close

₹ 80.31

Volume

1257

Mkt Cap ( ₹ Cr)

₹ 106.45

High

₹ 81.99

Low

₹ 78.59

52 Week High

₹ 92.52

52 Week Low

₹ 61.00

Book Value Per Share

₹ 37.67

Dividend Yield

₹ 0.00

Face Value

₹₹10.00

What's Your Call?

Collective community sentiment on Concord Drugs Ltd

Your Vote -

Buy

86.67%

Hold

0.00%

Sell

13.33%

86.67%

15 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Concord Drugs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Concord Drugs Q1 net profit zooms 909.09% at Rs 1.11 cr

    25 Aug 2026, 4:00PM The company reported standalone net profit of Rs 1.11 crore for the quarter ended June 30, 2026 as compared to Rs 0.11 crore in the same period last y
  • Concord Drugs - Financial Results For Quarter Ended 30 June 2026

    10 Aug 2026, 5:38PM Board of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 2026
  • Concord Drugs - Board Meeting Outcome for Outcome Of Board Meeting

    10 Aug 2026, 5:32PM Outcome of Board meeting
  • Concord Drugs - Board Meeting Intimation for Quarterly Results

    3 Aug 2026, 5:22PM Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and ap
  • Concord Drugs has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    21 Jul 2026, 10:30PM As of June 2026, 45.08% is owned by Indian Promoters and 54.92% by Public. <p align=justify> Top three Promoters holding highest number of shares of C
  • Concord Drugs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    13 Jul 2026, 6:50PM Certificate under Reg 74(5) of SEBI (DP) Regulations

Key fundamentals

Evaluate the intrinsic value of Concord Drugs Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 60.1243 48.9734 47.8258 46.5061 44.7948
Liabilities 60.1243 48.9734 47.8258 46.5061 44.7948
Equity 13.175 10 10 9.3155 8.7437
Gross Profit 4.2305 3.7633 3.6772 4.3437 5.5924
Net Profit 1.0374 0.2957 0.4194 0.8922 1.5943
Cash From Operating Activities -7.3663 3.1631 1.9598 2.2448 0.7741
NPM(%) 1.36 0.8 0.96 1.73 2.7
Revenue 75.8486 36.9321 43.2607 51.3143 58.9564
Expenses 71.6181 33.1688 39.5835 46.9706 53.3639
ROE(%) 2.09 0.59 0.84 1.79 3.21

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Concord Drugs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 863.00 -0.52 21.76 46.13 -26.19 0.58
Lotus Eye Hospital and Institute Ltd 109.90 -0.68 1563.29 168.08 0.39 0.00
Bharat Immunological and Biologicals Corporation Ltd 15.42 0.72 0.00 348.98 -39.50 0.00
Astec Lifesciences Ltd 552.30 -3.93 0.00 180.08 -363.14 0.00

Company Info

Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511 Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord's three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce `AMCRYLATE' and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. 2015 -Concord Drugs Ltd are listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.

Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511 Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord's three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce `AMCRYLATE' and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. 2015 -Concord Drugs Ltd are listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.

Parent Organisation

Concord Drugs Ltd.

Founded

24/04/1995

Managing Director

Mr.S Nagi Reddy

NSE Symbol

FAQ